- Home
- IPHA
as 12-20-2024 2:38pm EST
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 178.0M | IPO Year: | 2019 |
| Target Price: | $11.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.29 - $3.51 | Next Earning Date: | 09-12-2024 |
| Revenue: | $36,202,722 | Revenue Growth: | -35.37% |
| Revenue Growth (this year): | -42.12% | Revenue Growth (next year): | 102.87% |
Latest Innate Pharma S.A. ADS News
IPHA Breaking Stock News: Dive into IPHA Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Simply Wall St.
10 days ago
3 Promising Penny Stocks With Market Caps Under US$300M
TipRanks
12 days ago
Innate Pharma SA Reveals Promising Lacutamab Trial Results
Business Wire
13 days ago
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
MT Newswires
16 days ago
Sector Update: Health Care Stocks Edge Higher Premarket Friday
MT Newswires
16 days ago
Innate Pharma, Institute for Follicular Lymphoma Collaborate to Study IPH6501 in Follicular Lymphoma
Business Wire
16 days ago
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
Business Wire
19 days ago
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
Compare IPHA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPHA Innate Pharma S.A. ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.